Valproate Suppresses Status Epilepticus Induced by 4-Aminopyridine in CA1 Hippocampus Region

Epilepsia

Volumn 44, Issue 11, 2003, Pages 1375-1379

  Martín, Eduardo D ^a,b   Pozo, Miguel A ^a  

^a UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^b UNIVERSITY OF CASTILLA LA MANCHA   (Spain)

Author keywords

4 Aminopyridine; Hippocampus; Status epilepticus; Valproate

Indexed keywords

4 AMINOPYRIDINE; ANTICONVULSIVE AGENT; VALPROIC ACID;

ANIMAL MODEL; ANTICONVULSANT ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; EPILEPSY; EPILEPTIC STATE; HIPPOCAMPUS; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; SEIZURE;

4-AMINOPYRIDINE; ANIMALS; CARBAMAZEPINE; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTROENCEPHALOGRAPHY; HIPPOCAMPUS; INJECTIONS; MALE; PHENYTOIN; RATS; RATS, WISTAR; STATUS EPILEPTICUS; VALPROIC ACID;

EID: 0242575067     PISSN: 00139580     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1528-1157.2003.11603.x     Document Type: Article

References (24)

1. Lowenstein DH. Status epilepticus: an overview of the clinical problem. Epilepsia 1999;40(suppl 1):S3-8.
2. Kapur J. Status epilepticus in epileptogenesis. Curr Opin Neurol 1999;12:191-5.
3. Treiman DM. Generalized convulsive status epilepticus in the adult. Epilepsia 1993;34(suppl 1):S2-11.
4. Engel J Jr, Ludwig BI, Fetell M. Prolonged partial complex status epilepticus: EEG and behavioural observations. Neurology 1978;28:863-9.
5. Privitera M. Complex partial status epilepticus. Neurology 1997;48:1140-1.
6. Treiman DM, Heinemann U. Experimental models of status epilepticus. In: Engel JJ, Pedley TA, eds. Epilepsy: a comprehensive textbook. Philadelphia: Lippincott-Raven, 1997;1:443-54.
7. Löscher W. Valproate: a reappraisal of its pharmacodynamic properties and mechanisms of action. Prog Neurobiol 1999;58:31-59.
8. Löscher W. Basic pharmacology of valproate: a review after 35 years of clinical use for the treatment of epilepsy. CNS Drugs 2002;16:669-94.
9. Berkovic SF, Bladin PF. Absence status in adults. Clin Exp Neurol 1983;19:198-207.
10. Lowe MR, DeToledo JC, Velarza N, et al. Efficacy, safety, and tolerability of fast i.v. loading of valproate in patients with seizures and status epilepticus. Epilepsia 1998;39(suppl 6):235.
11. Alehan FK, Morton LD, Pellock JM. Treatment of absence status with intravenous valproate. Neurology 1999;52:889-90.
12. Kaplan PW. Intravenous valproate treatment of generalized nonconvulsive status epilepticus. Clin Electroencephalogr 1999;30:1-4.
13. Hodges BM, Mazur JE. Intravenous valproate in status epilepticus. Ann Pharmacother 2001;35:1465-70.
14. Paxinos G, Watson C. The rat brain in stereotaxic coordinates. New York: Academic Press, 1982.
15. Towne AR, Pellock JM, Ko D, et al. Determinants of mortality in status epilepticus. Epilepsia 1994;35:27-34.
16. Yaffe K, Lowenstein DH. Prognostic factors of pentobarbital therapy for refractory generalized status epilepticus. Neurology 1993;43:895-900.
17. Hönack D, Löscher W. Intravenous valproate: onset and duration of anticonvulsant activity against a series of electroconvulsions in comparison with diazepam and phenytoin. Epilepsy Res 1992;13:215-21.
18. Walton NY, Treiman DM. Valproic acid treatment of experimental status epilepticus. Epilepsy Res 1992;12:199-205.
19. 14C]glucose into amino acids. Neurochem Res 1982;7:1089-105.
20. o in the hippocampal slice. Brain Res 1986;386:1-11.
21. Godin Y, Heiner L, Mark J, et al. Effects of DI-n-propylacetate, and anticonvulsive compound, on GABA metabolism. J Neurochem 1969;16:869-73.
22. Griffith WH, Taylor L. Sodium valproate decreases synaptic potentiation and epileptiform activity in hippocampus. Brain Res 1988;474:155-64.
23. Löscher W. Valproate enhances GABA turnover in the substantia nigra. Brain Res 1989;501:198-203.
24. McLean MJ, Macdonald RL. Sodium valproate, but not ethosuximide, produces use- and voltage-dependent limitation of high frequency repetitive firing of action potentials of mouse central neurons in cell culture. J Pharmacol Exp Ther 1986;237:1001-11.